Elite Pharmaceuticals Inc (ELTP)

[carbonfiltered]

"The important thing here is the impact of this operation on shareholders. It removes the risk of serious dilution, as the company can (pretty much) fund its own development program. Operating expenses (including R&D) for the three months to September 30 came in at a little over $2 million. On hand at the end of that period totaled $12.6 million. Even without the generics revenues footing the bill, and taking the $1.8 million cost of revenue into account, the company is capitalized through 2018.